Given prior reports of ulcerative keratitis occurring in association with the IL-4 and IL-13 inhibitor dupilumab [2, 9], we hypothesize that the conjunctivitis and ocular surface inflammation known to be triggered by the IL-13 inhibitor tralokinumab may have been a contributing factor in this episode of PUK. Here, IL13 is linked to conjunctivitis.